Article 2 supplies definitions, including 'clinical study', 'clinical trial', 'low-intervention clinical trial', 'non-interventional study', 'investigational medicinal product (IMP)', 'auxiliary medicinal product', 'sponsor', 'investigator', 'subject', 'informed consent', 'protocol', 'serious adverse event', 'serious adverse reaction', 'suspected unexpected serious adverse reaction (SUSAR)', and 'serious breach'.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.